Successful Tocilizumab Treatment In A Patient With Human Herpesvirus 8-Positive And Human Immunodeficiency Virus-Negative Multicentric Castleman's Disease Of Plasma Cell Type Nonresponsive To Rituximab-CVP Therapy

G. Müzes, F. Sípos, Judit Csomor, Lídia Sréter

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We present and discuss the case of a HIV-negative female finally diagnosed upon histopathologic and molecular biologic evaluations with human herpesvirus 8 (HHV8)-positive multicentric Castleman's disease (MCD) of plasma cell type, but with no detectable HHV8-DNA in peripheral blood. She failed to respond to combination immunosuppressive therapeutic trials of corticosteroids and azathioprine, and neither an immunochemotherapy of rituximab-CVP (R-CVP) induced disease resolution. However, monoclonal anti-IL-6R antibody (tocilizumab) immunotherapy resulted in beneficial disease stabilization. A control lymph node biopsy indicated mild polyclonal plasmacytosis, and a negative HHV8 determination. The patient is still receiving tocilizumab. This case emphasizes the individual nature of MCD requiering more personalized disease management.

Original languageEnglish
Pages (from-to)668-674
Number of pages7
JournalAPMIS
Volume121
Issue number7
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Human Herpesvirus 8
Plasma Cells
HIV
Azathioprine
Immunosuppressive Agents
Disease Management
Immunotherapy
Adrenal Cortex Hormones
Therapeutics
Lymph Nodes
Biopsy
Antibodies
DNA
Rituximab
tocilizumab
Multi-centric Castleman's Disease

Keywords

  • Human herpesvirus 8
  • Interleukin-6
  • Multicentric Castleman's disease
  • Rituximab
  • Tocilizumab

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Microbiology (medical)
  • Immunology and Allergy

Cite this

@article{f8fd93d87e7f43618c5a2b9e473f3edc,
title = "Successful Tocilizumab Treatment In A Patient With Human Herpesvirus 8-Positive And Human Immunodeficiency Virus-Negative Multicentric Castleman's Disease Of Plasma Cell Type Nonresponsive To Rituximab-CVP Therapy",
abstract = "We present and discuss the case of a HIV-negative female finally diagnosed upon histopathologic and molecular biologic evaluations with human herpesvirus 8 (HHV8)-positive multicentric Castleman's disease (MCD) of plasma cell type, but with no detectable HHV8-DNA in peripheral blood. She failed to respond to combination immunosuppressive therapeutic trials of corticosteroids and azathioprine, and neither an immunochemotherapy of rituximab-CVP (R-CVP) induced disease resolution. However, monoclonal anti-IL-6R antibody (tocilizumab) immunotherapy resulted in beneficial disease stabilization. A control lymph node biopsy indicated mild polyclonal plasmacytosis, and a negative HHV8 determination. The patient is still receiving tocilizumab. This case emphasizes the individual nature of MCD requiering more personalized disease management.",
keywords = "Human herpesvirus 8, Interleukin-6, Multicentric Castleman's disease, Rituximab, Tocilizumab",
author = "G. M{\"u}zes and F. S{\'i}pos and Judit Csomor and L{\'i}dia Sr{\'e}ter",
year = "2013",
month = "7",
doi = "10.1111/apm.12029",
language = "English",
volume = "121",
pages = "668--674",
journal = "Acta Pathologica Microbiologica et Immunologica Scandinavica - Section B Microbiology",
issn = "0365-5555",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Successful Tocilizumab Treatment In A Patient With Human Herpesvirus 8-Positive And Human Immunodeficiency Virus-Negative Multicentric Castleman's Disease Of Plasma Cell Type Nonresponsive To Rituximab-CVP Therapy

AU - Müzes, G.

AU - Sípos, F.

AU - Csomor, Judit

AU - Sréter, Lídia

PY - 2013/7

Y1 - 2013/7

N2 - We present and discuss the case of a HIV-negative female finally diagnosed upon histopathologic and molecular biologic evaluations with human herpesvirus 8 (HHV8)-positive multicentric Castleman's disease (MCD) of plasma cell type, but with no detectable HHV8-DNA in peripheral blood. She failed to respond to combination immunosuppressive therapeutic trials of corticosteroids and azathioprine, and neither an immunochemotherapy of rituximab-CVP (R-CVP) induced disease resolution. However, monoclonal anti-IL-6R antibody (tocilizumab) immunotherapy resulted in beneficial disease stabilization. A control lymph node biopsy indicated mild polyclonal plasmacytosis, and a negative HHV8 determination. The patient is still receiving tocilizumab. This case emphasizes the individual nature of MCD requiering more personalized disease management.

AB - We present and discuss the case of a HIV-negative female finally diagnosed upon histopathologic and molecular biologic evaluations with human herpesvirus 8 (HHV8)-positive multicentric Castleman's disease (MCD) of plasma cell type, but with no detectable HHV8-DNA in peripheral blood. She failed to respond to combination immunosuppressive therapeutic trials of corticosteroids and azathioprine, and neither an immunochemotherapy of rituximab-CVP (R-CVP) induced disease resolution. However, monoclonal anti-IL-6R antibody (tocilizumab) immunotherapy resulted in beneficial disease stabilization. A control lymph node biopsy indicated mild polyclonal plasmacytosis, and a negative HHV8 determination. The patient is still receiving tocilizumab. This case emphasizes the individual nature of MCD requiering more personalized disease management.

KW - Human herpesvirus 8

KW - Interleukin-6

KW - Multicentric Castleman's disease

KW - Rituximab

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=84879500926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879500926&partnerID=8YFLogxK

U2 - 10.1111/apm.12029

DO - 10.1111/apm.12029

M3 - Article

C2 - 23163599

AN - SCOPUS:84879500926

VL - 121

SP - 668

EP - 674

JO - Acta Pathologica Microbiologica et Immunologica Scandinavica - Section B Microbiology

JF - Acta Pathologica Microbiologica et Immunologica Scandinavica - Section B Microbiology

SN - 0365-5555

IS - 7

ER -